NEW YORK, NY / ACCESS Newswire / April 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...

NEW YORK, NY / ACCESS Newswire / April 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Supernus Pharmaceuticals got a positive adjustment to its Relative Strength (RS) Rating, from 67 to 81. Please watch the ...

Supernus Pharmaceuticals has been treading water for the past six months, recording a small loss of 1.6% while holding steady at $31.52. However, the stock is beating the S&P 500’s 7% decline during ...

Detailed price information for Collegium Pharma (COLL-Q) from The Globe and Mail including charting and trades.

Supernus' neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients ...

With a diverse portfolio of eight FDA-approved medications targeting neurological conditions, Supernus Pharmaceuticals (NASDAQ:SUPN) develops and markets treatments for central nervous system ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

A downtrend has been apparent in Supernus Pharmaceuticals (SUPN) lately with too much selling pressure. The stock has declined 20.1% over the past four weeks. However, given the fact that it is ...